Lincoln Pharmaceuticals Reports FY26 Results, Recommends 18% Dividend
Lincoln Pharmaceuticals Limited announced its financial results for the year ending March 31, 2026, today, detailing a robust performance marked by growth across its key segments. The company recommended a dividend of 18% on its equity shares for the fiscal year 2025-26.The company reported a consolidated net profit of Rs. 87.89 crore for the fiscal year 2025-26, marking a 6.74% year-on-year increase compared to Rs. 82.35 crore in FY25. Revenue from Operations for FY26 reached Rs. 704.48 crore, showing a growth of 9.10% Y-o-Y. Furthermore, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs. 131.14 crore, reflecting a 5.78% growth...